ERBB2 and breast cancer: The APT study suggested that for patients with small tumors (≤3 cm) and HER2+ BC treated with weekly paclitaxel and trastuzumab followed by trastuzumab every 3 weeks (wTH), the 3-year DFS rate reached 98.7% (Tolaney et al., 2019).